Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

39.46 +0.30 (+0.77%)
Streaming Delayed Price Updated: 3:09 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,506,459
Open 39.04
Bid (Size) 39.46 (300)
Ask (Size) 39.47 (300)
Prev. Close 39.16
Today's Range 38.98 - 39.50
52wk Range 24.05 - 41.24
Shares Outstanding 388,132,400
Dividend Yield 2.23%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model. 
Via Investor's Business Daily
News headline image
3 Value Stocks with Warning Signs
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Topics Supply Chain

Performance

YTD
+53.0%
+53.0%
1 Month
+7.7%
+7.7%
3 Month
+9.9%
+9.9%
6 Month
+15.2%
+15.2%
1 Year
+52.9%
+52.9%

More News

Read More
News headline image
3 Low-Volatility Stocks We Find Risky
Via StockStory
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?
Via StockStory
Topics Stocks Supply Chain
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
How Do Investors Really Feel About Royalty Pharma? ↗
Via Benzinga
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
Via MarketMinute
Topics Intellectual Property
News headline image
Royalty Pharma (NASDAQ:RPRX) Q3 2025 Earnings Beat Estimates and Raise Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Royalty Pharma Reports Third Quarter 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗
Via Benzinga
Topics Economy
News headline image
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
What To Expect From Royalty Pharma’s (RPRX) Q3 Earnings
Via StockStory
Topics Artificial Intelligence
News headline image
ROYALTY PHARMA PLC-CL A (RPRX) Shows Strong Technicals and a High-Quality Breakout Setup ↗
Via Chartmill
News headline image
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗
Via MarketBeat
News headline image
2 Reasons to Avoid RPRX and 1 Stock to Buy Instead
Via StockStory
Topics Government Stocks Supply Chain
News headline image
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data ↗
Via MarketBeat
News headline image
Royalty Pharma Declares Fourth Quarter 2025 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
3 Healthcare Stocks We Keep Off Our Radar
Via StockStory
Topics Economy Stocks
News headline image
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
From Royalty Pharma plc
Via GlobeNewswire
News headline image
1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore
Via StockStory
News headline image
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
From Royalty Pharma plc
Via GlobeNewswire

Frequently Asked Questions

Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
The current price of Royalty Pharma plc - Class A Ordinary Shares is 39.46
When was Royalty Pharma plc - Class A Ordinary Shares last traded?
The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 11/18/25 03:09 PM ET
What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 15.32B
How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
Royalty Pharma plc - Class A Ordinary Shares has 15B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.